Yasuyo Ohi Selected Research

Yasuyo Ohi Research Topics

Disease

29	Breast Neoplasms (Breast Cancer) 03/2024 - 03/2002
19	Neoplasms (Cancer) 03/2024 - 08/2002
9	Ductal Carcinoma 02/2020 - 03/2002
7	Triple Negative Breast Neoplasms 09/2023 - 04/2011
6	Carcinoma (Carcinomatosis) 12/2018 - 03/2002
5	Neoplasm Metastasis (Metastasis) 11/2023 - 04/2013
4	Lymphatic Metastasis 09/2018 - 01/2006
3	Lobular Carcinoma 01/2024 - 11/2014
3	Noninfiltrating Intraductal Carcinoma (DCIS) 03/2021 - 08/2002
1	Pathologic Complete Response 01/2019
1	Glioma (Gliomas) 03/2017
1	Astrocytoma (Pilocytic Astrocytoma) 03/2017
1	Mucocele 04/2011
1	Cysts 04/2011
1	Bone Fractures (Bone Fracture) 07/2010
1	Carcinogenesis 05/2007

Drug/Important Bio-Agent (IBA)

6	Proteins (Proteins, Gene)FDA Link 11/2023 - 03/2002
6	ParaffinIBA 10/2011 - 03/2002
5	human ERBB2 proteinIBA 10/2023 - 01/2013
5	Messenger RNA (mRNA)IBA 01/2022 - 03/2002
5	Estrogen ReceptorsIBA 12/2017 - 03/2002
4	Keratin-19 (Keratin 19)IBA 11/2023 - 04/2013
4	Nucleic AcidsIBA 01/2022 - 04/2013
3	EnzymesIBA 11/2023 - 11/2014
3	Hormones (Hormone)IBA 10/2023 - 01/2006
3	AndrogensIBA 02/2020 - 11/2014
3	SERPIN-B5 (maspin)IBA 12/2018 - 08/2002
3	Trastuzumab (Herceptin)FDA Link 10/2018 - 01/2013
3	AntibodiesIBA 04/2011 - 08/2002
2	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 11/2023
2	CytokinesIBA 09/2023 - 12/2017
2	GlucocorticoidsIBA 08/2023 - 02/2020
2	Progesterone Receptors (Progesterone Receptor)IBA 01/2022 - 05/2007
2	Eosine Yellowish-(YS) (Eosin)IBA 03/2021 - 01/2016
2	Growth Factor ReceptorsIBA 02/2020 - 01/2016
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2020 - 02/2018
2	Peptides (Polypeptides)IBA 07/2018 - 08/2014
2	Biomarkers (Surrogate Marker)IBA 01/2017 - 06/2015
2	Indicators and Reagents (Reagents)IBA 10/2011 - 03/2002
2	Aldehyde Dehydrogenase 1 FamilyIBA 10/2011 - 03/2011
2	Estrogen Receptor alphaIBA 05/2007 - 08/2006
2	StreptavidinIBA 08/2002 - 03/2002
2	Biotin (Vitamin H)FDA Link 08/2002 - 03/2002
1	InterleukinsIBA 09/2023
1	Interleukin-17 (Interleukin 17)IBA 09/2023
1	VimentinIBA 01/2019
1	multidrug resistance-associated protein 1IBA 01/2019
1	Aromatase (CYP19)IBA 07/2018
1	Testosterone CongenersIBA 12/2017
1	Estradiol Congeners (Synthetic Estrogens)IBA 12/2017
1	GadoliniumIBA 03/2017
1	NimustineIBA 03/2017
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 03/2017
1	Temozolomide (Temodar)FDA LinkGeneric 03/2017
1	Lapatinib (GW572016)FDA Link 01/2017
1	Capecitabine (Xeloda)FDA Link 01/2017
1	Phenobarbital (Luminal)FDA Link 02/2016
1	Estrogens (Estrogen)FDA Link 02/2016
1	ErbB Receptors (EGF Receptor)IBA 01/2016
1	Hematoxylin (Haematoxylon)IBA 01/2016
1	Androgen Receptors (Androgen Receptor)IBA 11/2014
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 08/2014
1	MucinsIBA 04/2011
1	Anastrozole (Arimidex)FDA LinkGeneric 07/2010
1	Aromatase InhibitorsIBA 07/2010
1	Diphosphonates (Bisphosphonates)IBA 07/2010
1	Protein Isoforms (Isoforms)IBA 08/2006
1	Formaldehyde (Formol)FDA Link 08/2006
1	Monoclonal AntibodiesIBA 08/2006
1	Estrogen Receptor betaIBA 08/2006

Therapy/Procedure

10	Therapeutics 01/2024 - 07/2010
4	Drug Therapy (Chemotherapy) 10/2023 - 03/2017
3	Mastectomy (Mammectomy) 07/2019 - 03/2002
2	Segmental Mastectomy (Lumpectomy) 08/2002 - 03/2002
1	Neoadjuvant Therapy 01/2019
1	Adjuvant Chemotherapy 10/2018
1	Radiotherapy 03/2017